GlassScriptPhysician profile
Scott Ubillos
NPI 1396728911
$3,864.98
in general payments reported to CMS, 2019-2025
17 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,063 · 2020: $643 · 2021: $733 · 2022: $628 · 2023: $305 · 2024: $135 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $796.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $806.46 | 2019-2025 | Apretude, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $664.33 | 2019-2024 | |
| Janssen Biotech, INC. | $593.62 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $441.79 | 2019-2025 | Pifeltro, Dificid, Delstrigo |
| Theratechnologies INC. | $440.98 | 2019-2025 | Trogarzo, Egrifta |
| Insmed, INC. | $317.76 | 2019-2025 | Arikayce, Brinsupri |
| Paratek Pharmaceuticals, INC. | $154.86 | 2019-2021 | |
| Abbvie INC. | $126.66 | 2021-2023 | Mavyret |
| La Jolla Pharmaceutical Company | $120.93 | 2022 | |
| Astellas Pharma US INC | $54.71 | 2022-2025 | Cresemba |
| Janssen Scientific Affairs, LLC | $33.62 | 2019-2022 | |
| Hologic Sales and Service, LLC | $25.24 | 2024 | Thinprep 2000 Processor, Aptima |
| Abbott Laboratories | $24.27 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $17.80 | 2019 | |
| Melinta Therapeutics, LLC | $17.21 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14.18 | 2021 | |
| Emd Serono, INC. | $10.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Ubillos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.